Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume

Pharming Group (NASDAQ:PHAR) shares saw an uptick in trading volume on Tuesday . 20,018 shares were traded during mid-day trading, an increase of 335% from the previous session’s volume of 4,597 shares.The stock last traded at $8.05 and had previously closed at $8.25.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Thursday, September 26th.

Pharming Group Trading Up 4.1 %

The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. The business has a 50-day simple moving average of $7.79 and a 200-day simple moving average of $8.84. The company has a market cap of $578.48 million, a PE ratio of -50.56 and a beta of 0.14.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The business had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same period in the previous year, the business posted $0.02 EPS. On average, analysts predict that Pharming Group will post -0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.